Literature DB >> 664752

Metabolism of papaverine IV. Urinary elimination of papaverine metabolites in man.

F M Belpaire, M T Rosseel, M G Bogaert.   

Abstract

1. A gas chromatographic method is described for the quantitative determination of the metabolites of papaverine in urine. 2. The urinary excretion of papaverine metabolites was studied in man. About 50% of the metabolites of papaverine are excreted in the urine within 48 h. 6-Desmethylpapaverine is the major metabolite in the urine. The metabolites are excreted almost completely in conjugated form.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 664752     DOI： 10.3109/00498257809060953

Source DB:  PubMed          Journal:  Xenobiotica        ISSN： 0049-8254            Impact factor:   1.908


  5 in total

1.  Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation.

Authors:  Zhude Tu; Jinbin Xu; Lynne A Jones; Shihong Li; Robert H Mach
Journal:  Nucl Med Biol       Date:  2010-03-06       Impact factor: 2.408

2.  Using Papaverine and Its Metabolites, 6-Desmethyl Papaverine and 4',6-Didesmethyl Papaverine as Biomarkers to Improve the Detection Time of Heroin Use.

Authors:  Carl E Wolf; Kaitlin L Pierce; Brett L Goldfine; Carrol R Nanco; Justin L Poklis; William J Korzun
Journal:  J Anal Toxicol       Date:  2019-09-10       Impact factor: 3.367

3.  Toxicity assessment of papaverine hydrochloride and papaverine-derived metabolites in primary cultures of rat hepatocytes.

Authors:  J C Davila; C G Reddy; P J Davis; D Acosta
Journal:  In Vitro Cell Dev Biol       Date:  1990-05

4.  The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate.

Authors:  Z Vargay; T Deutsch; I Szatmári; T Szüts; P Várkonyi; S Kerpel-Fronius; S Eckhardt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

5.  Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass.

Authors:  W G Kramer; A Romagnoli
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.